IL94549A - A pharmaceutical preparation containing glutamine - Google Patents

A pharmaceutical preparation containing glutamine

Info

Publication number: IL94549A
Authority: IL; Israel
Prior art keywords: gln; nitrogen; animals; amino acid; bcaa
Prior art date: 1989-06-02

Application number

IL9454990A

Other languages

English (en)

Hebrew (he)

Other versions

IL94549A0 (en

Original Assignee

Brigham & Womens Hospital

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-06-02

Filing date

1990-05-29

Publication date

1996-08-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23419606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL94549(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-05-29 Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital

1991-03-10 Publication of IL94549A0 publication Critical patent/IL94549A0/xx

1996-08-04 Publication of IL94549A publication Critical patent/IL94549A/en

Links

239000008194 pharmaceutical composition Substances 0.000 title claims description 10
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 title abstract description 671
230000001925 catabolic effect Effects 0.000 claims abstract description 25
230000036737 immune function Effects 0.000 claims abstract description 21
230000001010 compromised effect Effects 0.000 claims abstract description 20
230000004064 dysfunction Effects 0.000 claims description 17
230000006378 damage Effects 0.000 claims description 13
238000001356 surgical procedure Methods 0.000 claims description 12
238000002512 chemotherapy Methods 0.000 claims description 8
238000001990 intravenous administration Methods 0.000 claims description 8
241000124008 Mammalia Species 0.000 claims description 7
206010040047 Sepsis Diseases 0.000 claims description 5
235000021590 normal diet Nutrition 0.000 claims description 5
241000282414 Homo sapiens Species 0.000 claims description 4
206010012601 diabetes mellitus Diseases 0.000 claims description 4
238000001959 radiotherapy Methods 0.000 claims description 4
230000035699 permeability Effects 0.000 abstract description 13
206010033603 Pancreatic atrophy Diseases 0.000 abstract description 12
238000010322 bone marrow transplantation Methods 0.000 abstract description 11
238000011084 recovery Methods 0.000 abstract description 10
230000006735 deficit Effects 0.000 abstract description 8
206010067745 Intestinal mucosal atrophy Diseases 0.000 abstract description 3
208000037273 Pathologic Processes Diseases 0.000 abstract description 3
230000009054 pathological process Effects 0.000 abstract description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 298
229940024606 amino acid Drugs 0.000 description 188
235000001014 amino acid Nutrition 0.000 description 188
150000001413 amino acids Chemical class 0.000 description 185
241001465754 Metazoa Species 0.000 description 178
229910052757 nitrogen Inorganic materials 0.000 description 150
150000005693 branched-chain amino acids Chemical class 0.000 description 94
239000000243 solution Substances 0.000 description 67
235000005911 diet Nutrition 0.000 description 64
238000000034 method Methods 0.000 description 62
230000000694 effects Effects 0.000 description 60
235000021476 total parenteral nutrition Nutrition 0.000 description 58
230000037213 diet Effects 0.000 description 57
238000001802 infusion Methods 0.000 description 57
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 53
230000003834 intracellular effect Effects 0.000 description 51
235000002639 sodium chloride Nutrition 0.000 description 50
230000000968 intestinal effect Effects 0.000 description 48
239000011780 sodium chloride Substances 0.000 description 48
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 45
241000700159 Rattus Species 0.000 description 44
210000004369 blood Anatomy 0.000 description 40
239000008280 blood Substances 0.000 description 40
238000002271 resection Methods 0.000 description 40
235000018102 proteins Nutrition 0.000 description 38
102000004169 proteins and genes Human genes 0.000 description 38
108090000623 proteins and genes Proteins 0.000 description 38
230000037396 body weight Effects 0.000 description 37
210000002381 plasma Anatomy 0.000 description 37
210000001035 gastrointestinal tract Anatomy 0.000 description 35
210000002027 skeletal muscle Anatomy 0.000 description 34
230000004907 flux Effects 0.000 description 32
235000004554 glutamine Nutrition 0.000 description 32
239000000203 mixture Substances 0.000 description 32
241000282472 Canis lupus familiaris Species 0.000 description 29
230000002980 postoperative effect Effects 0.000 description 29
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 26
238000004458 analytical method Methods 0.000 description 26
229960002949 fluorouracil Drugs 0.000 description 26
210000001519 tissue Anatomy 0.000 description 26
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 25
238000011282 treatment Methods 0.000 description 24
230000035611 feeding Effects 0.000 description 23
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 22
210000003205 muscle Anatomy 0.000 description 22
235000013350 formula milk Nutrition 0.000 description 21
210000001630 jejunum Anatomy 0.000 description 21
210000002700 urine Anatomy 0.000 description 21
210000003405 ileum Anatomy 0.000 description 20
210000004027 cell Anatomy 0.000 description 19
239000000523 sample Substances 0.000 description 19
210000000813 small intestine Anatomy 0.000 description 19
239000003797 essential amino acid Substances 0.000 description 18
229930195712 glutamate Natural products 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
230000015556 catabolic process Effects 0.000 description 17
235000020776 essential amino acid Nutrition 0.000 description 17
230000029142 excretion Effects 0.000 description 17
235000016709 nutrition Nutrition 0.000 description 17
210000000496 pancreas Anatomy 0.000 description 17
230000004044 response Effects 0.000 description 16
235000015097 nutrients Nutrition 0.000 description 15
230000008859 change Effects 0.000 description 14
102000004190 Enzymes Human genes 0.000 description 13
108090000790 Enzymes Proteins 0.000 description 13
229940088598 enzyme Drugs 0.000 description 13
230000035764 nutrition Effects 0.000 description 13
230000003247 decreasing effect Effects 0.000 description 12
230000012010 growth Effects 0.000 description 12
210000000936 intestine Anatomy 0.000 description 12
229910021529 ammonia Inorganic materials 0.000 description 11
230000007423 decrease Effects 0.000 description 11
238000002347 injection Methods 0.000 description 11
239000007924 injection Substances 0.000 description 11
238000005259 measurement Methods 0.000 description 11
235000016236 parenteral nutrition Nutrition 0.000 description 11
238000002360 preparation method Methods 0.000 description 11
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
201000010099 disease Diseases 0.000 description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
-1 glucose oligosaccharides Chemical class 0.000 description 10
JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 10
229960000511 lactulose Drugs 0.000 description 10
PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 10
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 10
230000002485 urinary effect Effects 0.000 description 10
230000002496 gastric effect Effects 0.000 description 9
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 9
230000001228 trophic effect Effects 0.000 description 9
208000027418 Wounds and injury Diseases 0.000 description 8
210000001015 abdomen Anatomy 0.000 description 8
238000000540 analysis of variance Methods 0.000 description 8
235000019197 fats Nutrition 0.000 description 8
208000014674 injury Diseases 0.000 description 8
210000004347 intestinal mucosa Anatomy 0.000 description 8
210000004185 liver Anatomy 0.000 description 8
230000002503 metabolic effect Effects 0.000 description 8
230000004060 metabolic process Effects 0.000 description 8
239000003182 parenteral nutrition solution Substances 0.000 description 8
238000011870 unpaired t-test Methods 0.000 description 8
206010002091 Anaesthesia Diseases 0.000 description 7
206010003694 Atrophy Diseases 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 7
241000282412 Homo Species 0.000 description 7
102000018690 Trypsinogen Human genes 0.000 description 7
108010027252 Trypsinogen Proteins 0.000 description 7
230000004075 alteration Effects 0.000 description 7
230000037005 anaesthesia Effects 0.000 description 7
230000037444 atrophy Effects 0.000 description 7
230000007123 defense Effects 0.000 description 7
230000000378 dietary effect Effects 0.000 description 7
239000003814 drug Substances 0.000 description 7
235000013305 food Nutrition 0.000 description 7
239000000446 fuel Substances 0.000 description 7
230000006870 function Effects 0.000 description 7
206010020718 hyperplasia Diseases 0.000 description 7
208000015181 infectious disease Diseases 0.000 description 7
210000004698 lymphocyte Anatomy 0.000 description 7
239000000463 material Substances 0.000 description 7
235000019624 protein content Nutrition 0.000 description 7
UNZMYCAEMNVPHX-UHFFFAOYSA-M sodium p-aminohippurate Chemical compound [Na+].NC1=CC=C(C(=O)NCC([O-])=O)C=C1 UNZMYCAEMNVPHX-UHFFFAOYSA-M 0.000 description 7
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
210000000709 aorta Anatomy 0.000 description 6
238000001574 biopsy Methods 0.000 description 6
230000001186 cumulative effect Effects 0.000 description 6
235000014105 formulated food Nutrition 0.000 description 6
210000003090 iliac artery Anatomy 0.000 description 6
238000007912 intraperitoneal administration Methods 0.000 description 6
239000007788 liquid Substances 0.000 description 6
238000007427 paired t-test Methods 0.000 description 6
229960001412 pentobarbital Drugs 0.000 description 6
230000003442 weekly effect Effects 0.000 description 6
230000004584 weight gain Effects 0.000 description 6
235000019786 weight gain Nutrition 0.000 description 6
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
102000013142 Amylases Human genes 0.000 description 5
108010065511 Amylases Proteins 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 5
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
241000700157 Rattus norvegicus Species 0.000 description 5
235000004279 alanine Nutrition 0.000 description 5
235000019418 amylase Nutrition 0.000 description 5
210000001367 artery Anatomy 0.000 description 5
230000003115 biocidal effect Effects 0.000 description 5
230000017531 blood circulation Effects 0.000 description 5
210000001772 blood platelet Anatomy 0.000 description 5
239000004202 carbamide Substances 0.000 description 5
229940109239 creatinine Drugs 0.000 description 5
230000003292 diminished effect Effects 0.000 description 5
229940079593 drug Drugs 0.000 description 5
210000001842 enterocyte Anatomy 0.000 description 5
244000144993 groups of animals Species 0.000 description 5
210000000265 leukocyte Anatomy 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
230000036961 partial effect Effects 0.000 description 5
239000000047 product Substances 0.000 description 5
235000013930 proline Nutrition 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
239000000758 substrate Substances 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
239000004382 Amylase Substances 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
208000028399 Critical Illness Diseases 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
102000010911 Enzyme Precursors Human genes 0.000 description 4
108010062466 Enzyme Precursors Proteins 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
102000009127 Glutaminase Human genes 0.000 description 4
108010073324 Glutaminase Proteins 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
102000001554 Hemoglobins Human genes 0.000 description 4
108010054147 Hemoglobins Proteins 0.000 description 4
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
102000004882 Lipase Human genes 0.000 description 4
108090001060 Lipase Proteins 0.000 description 4
239000004367 Lipase Substances 0.000 description 4
239000004698 Polyethylene Substances 0.000 description 4
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
235000020616 amino acid formula Nutrition 0.000 description 4
238000010171 animal model Methods 0.000 description 4
210000001185 bone marrow Anatomy 0.000 description 4
150000001720 carbohydrates Chemical class 0.000 description 4
235000014633 carbohydrates Nutrition 0.000 description 4
239000012153 distilled water Substances 0.000 description 4
239000003792 electrolyte Substances 0.000 description 4
230000002255 enzymatic effect Effects 0.000 description 4
235000012631 food intake Nutrition 0.000 description 4
235000013922 glutamic acid Nutrition 0.000 description 4
239000004220 glutamic acid Substances 0.000 description 4
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 4
208000024908 graft versus host disease Diseases 0.000 description 4
239000008187 granular material Substances 0.000 description 4
229960002897 heparin Drugs 0.000 description 4
229920000669 heparin Polymers 0.000 description 4
230000002962 histologic effect Effects 0.000 description 4
210000003111 iliac vein Anatomy 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
239000003978 infusion fluid Substances 0.000 description 4
210000003041 ligament Anatomy 0.000 description 4
235000019421 lipase Nutrition 0.000 description 4
230000035479 physiological effects, processes and functions Effects 0.000 description 4
229920000573 polyethylene Polymers 0.000 description 4
238000004321 preservation Methods 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
230000000717 retained effect Effects 0.000 description 4
235000004400 serine Nutrition 0.000 description 4
SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
235000013343 vitamin Nutrition 0.000 description 4
229940088594 vitamin Drugs 0.000 description 4
239000011782 vitamin Substances 0.000 description 4
229930003231 vitamin Natural products 0.000 description 4
208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
208000022559 Inflammatory bowel disease Diseases 0.000 description 3
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
102000008934 Muscle Proteins Human genes 0.000 description 3
108010074084 Muscle Proteins Proteins 0.000 description 3
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
238000009825 accumulation Methods 0.000 description 3
230000006978 adaptation Effects 0.000 description 3
150000001412 amines Chemical group 0.000 description 3
230000003872 anastomosis Effects 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
230000002238 attenuated effect Effects 0.000 description 3
230000004888 barrier function Effects 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
238000004364 calculation method Methods 0.000 description 3
235000019577 caloric intake Nutrition 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
235000020940 control diet Nutrition 0.000 description 3
238000012937 correction Methods 0.000 description 3
239000008121 dextrose Substances 0.000 description 3
235000015872 dietary supplement Nutrition 0.000 description 3
238000002224 dissection Methods 0.000 description 3
238000001493 electron microscopy Methods 0.000 description 3
235000020774 essential nutrients Nutrition 0.000 description 3
210000003020 exocrine pancreas Anatomy 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000000605 extraction Methods 0.000 description 3
239000012530 fluid Substances 0.000 description 3
230000037406 food intake Effects 0.000 description 3
210000004907 gland Anatomy 0.000 description 3
239000003862 glucocorticoid Substances 0.000 description 3
239000008103 glucose Substances 0.000 description 3
230000002489 hematologic effect Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
210000004731 jugular vein Anatomy 0.000 description 3
230000014759 maintenance of location Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
210000004877 mucosa Anatomy 0.000 description 3
230000004682 mucosal barrier function Effects 0.000 description 3
238000001964 muscle biopsy Methods 0.000 description 3
230000001590 oxidative effect Effects 0.000 description 3
210000004923 pancreatic tissue Anatomy 0.000 description 3
239000012188 paraffin wax Substances 0.000 description 3
244000052769 pathogen Species 0.000 description 3
230000001737 promoting effect Effects 0.000 description 3
210000003314 quadriceps muscle Anatomy 0.000 description 3
230000005855 radiation Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
230000028327 secretion Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
238000007619 statistical method Methods 0.000 description 3
208000003265 stomatitis Diseases 0.000 description 3
239000000126 substance Substances 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 3
210000001364 upper extremity Anatomy 0.000 description 3
210000003462 vein Anatomy 0.000 description 3
210000001631 vena cava inferior Anatomy 0.000 description 3
210000001835 viscera Anatomy 0.000 description 3
AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 2
CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
238000012935 Averaging Methods 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
102100032752 C-reactive protein Human genes 0.000 description 2
206010007733 Catabolic state Diseases 0.000 description 2
206010012735 Diarrhoea Diseases 0.000 description 2
108010016626 Dipeptides Proteins 0.000 description 2
LOJYQMFIIJVETK-WDSKDSINSA-N Gln-Gln Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O LOJYQMFIIJVETK-WDSKDSINSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
208000009329 Graft vs Host Disease Diseases 0.000 description 2
238000007696 Kjeldahl method Methods 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
206010067994 Mucosal atrophy Diseases 0.000 description 2
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
229920000153 Povidone-iodine Polymers 0.000 description 2
239000004792 Prolene Substances 0.000 description 2
206010037660 Pyrexia Diseases 0.000 description 2
206010041899 Stab wound Diseases 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
206010047700 Vomiting Diseases 0.000 description 2
210000000683 abdominal cavity Anatomy 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000003044 adaptive effect Effects 0.000 description 2
230000000735 allogeneic effect Effects 0.000 description 2
125000003368 amide group Chemical group 0.000 description 2
230000001195 anabolic effect Effects 0.000 description 2
210000003484 anatomy Anatomy 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000003160 anti-catabolic effect Effects 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
235000009697 arginine Nutrition 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000036760 body temperature Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000004087 circulation Effects 0.000 description 2
230000001143 conditioned effect Effects 0.000 description 2
210000002808 connective tissue Anatomy 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
230000003544 deproteinization Effects 0.000 description 2
238000001212 derivatisation Methods 0.000 description 2
238000013461 design Methods 0.000 description 2
235000018823 dietary intake Nutrition 0.000 description 2
235000020930 dietary requirements Nutrition 0.000 description 2
230000002183 duodenal effect Effects 0.000 description 2
235000020882 elemental diet Nutrition 0.000 description 2
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
235000013861 fat-free Nutrition 0.000 description 2
210000001105 femoral artery Anatomy 0.000 description 2
150000002308 glutamine derivatives Chemical class 0.000 description 2
102000005396 glutamine synthetase Human genes 0.000 description 2
108020002326 glutamine synthetase Proteins 0.000 description 2
230000036541 health Effects 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
230000002390 hyperplastic effect Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
238000002513 implantation Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
208000037817 intestinal injury Diseases 0.000 description 2
238000011835 investigation Methods 0.000 description 2
238000002350 laparotomy Methods 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
238000012417 linear regression Methods 0.000 description 2
210000003563 lymphoid tissue Anatomy 0.000 description 2
235000018977 lysine Nutrition 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
244000000010 microbial pathogen Species 0.000 description 2
238000000386 microscopy Methods 0.000 description 2
239000003226 mitogen Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
229910017604 nitric acid Inorganic materials 0.000 description 2
229940054441 o-phthalaldehyde Drugs 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
244000045947 parasite Species 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 2
229960001621 povidone-iodine Drugs 0.000 description 2
239000002243 precursor Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
238000000611 regression analysis Methods 0.000 description 2
210000002796 renal vein Anatomy 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
210000000574 retroperitoneal space Anatomy 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
229910001961 silver nitrate Inorganic materials 0.000 description 2
239000000344 soap Substances 0.000 description 2
239000007974 sodium acetate buffer Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
230000001629 suppression Effects 0.000 description 2
229940037128 systemic glucocorticoids Drugs 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000004448 titration Methods 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
238000007492 two-way ANOVA Methods 0.000 description 2
230000036269 ulceration Effects 0.000 description 2
238000012762 unpaired Student’s t-test Methods 0.000 description 2
210000003932 urinary bladder Anatomy 0.000 description 2
230000036325 urinary excretion Effects 0.000 description 2
239000004474 valine Substances 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
210000002620 vena cava superior Anatomy 0.000 description 2
230000009278 visceral effect Effects 0.000 description 2
230000008673 vomiting Effects 0.000 description 2
238000005303 weighing Methods 0.000 description 2
230000036642 wellbeing Effects 0.000 description 2
239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
208000021959 Abnormal metabolism Diseases 0.000 description 1
HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
206010050456 Anastomotic leak Diseases 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
229920003319 Araldite® Polymers 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
208000031648 Body Weight Changes Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
108010074051 C-Reactive Protein Proteins 0.000 description 1
102000011632 Caseins Human genes 0.000 description 1
108010076119 Caseins Proteins 0.000 description 1
235000019743 Choline chloride Nutrition 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
208000036828 Device occlusion Diseases 0.000 description 1
206010069802 Device related sepsis Diseases 0.000 description 1
206010013911 Dysgeusia Diseases 0.000 description 1
108010013369 Enteropeptidase Proteins 0.000 description 1
102100029727 Enteropeptidase Human genes 0.000 description 1
206010015719 Exsanguination Diseases 0.000 description 1
238000000729 Fisher's exact test Methods 0.000 description 1
241000233866 Fungi Species 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
206010017982 Gastrointestinal necrosis Diseases 0.000 description 1
OWOFCNWTMWOOJJ-WDSKDSINSA-N Gln-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O OWOFCNWTMWOOJJ-WDSKDSINSA-N 0.000 description 1
241000720950 Gluta Species 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
SKCKOFZKJLZSFA-UHFFFAOYSA-N L-Gulomethylit Natural products CC(O)C(O)C(O)C(O)CO SKCKOFZKJLZSFA-UHFFFAOYSA-N 0.000 description 1
LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
108090000942 Lactalbumin Proteins 0.000 description 1
102000004407 Lactalbumin Human genes 0.000 description 1
206010024264 Lethargy Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
229920002774 Maltodextrin Polymers 0.000 description 1
208000035346 Margins of Excision Diseases 0.000 description 1
206010028116 Mucosal inflammation Diseases 0.000 description 1
206010028124 Mucosal ulceration Diseases 0.000 description 1
201000010927 Mucositis Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
HSMNQINEKMPTIC-UHFFFAOYSA-N N-(4-aminobenzoyl)glycine Chemical compound NC1=CC=C(C(=O)NCC(O)=O)C=C1 HSMNQINEKMPTIC-UHFFFAOYSA-N 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
101100168117 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) con-8 gene Proteins 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
206010030216 Oesophagitis Diseases 0.000 description 1
241001306288 Ophrys fuciflora Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000035467 Pancreatic insufficiency Diseases 0.000 description 1
206010049082 Pancreatic mass Diseases 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
JDDHUROHDHPVIO-UHFFFAOYSA-N Piperazine citrate Chemical compound C1CNCCN1.C1CNCCN1.C1CNCCN1.OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O JDDHUROHDHPVIO-UHFFFAOYSA-N 0.000 description 1
108010071690 Prealbumin Proteins 0.000 description 1
102000007584 Prealbumin Human genes 0.000 description 1
108010009736 Protein Hydrolysates Proteins 0.000 description 1
ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
241000220317 Rosa Species 0.000 description 1
108010073771 Soybean Proteins Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
238000008050 Total Bilirubin Reagent Methods 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
206010046555 Urinary retention Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000005946 Xerostomia Diseases 0.000 description 1
241000209149 Zea Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
210000003815 abdominal wall Anatomy 0.000 description 1
230000007488 abnormal function Effects 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
208000037919 acquired disease Diseases 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
229960002648 alanylglutamine Drugs 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
230000037354 amino acid metabolism Effects 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229940025131 amylases Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
210000000436 anus Anatomy 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
238000010256 biochemical assay Methods 0.000 description 1
230000008238 biochemical pathway Effects 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000000476 body water Anatomy 0.000 description 1
230000004579 body weight change Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
239000000292 calcium oxide Substances 0.000 description 1
235000021236 calorie-restricted diet Nutrition 0.000 description 1
235000021074 carbohydrate intake Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
229960000603 cefalotin Drugs 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
229960003178 choline chloride Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001447 compensatory effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
235000007882 dietary composition Nutrition 0.000 description 1
235000021004 dietary regimen Nutrition 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
208000010643 digestive system disease Diseases 0.000 description 1
230000010339 dilation Effects 0.000 description 1
239000012470 diluted sample Substances 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
238000011833 dog model Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
206010013781 dry mouth Diseases 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
235000019564 dysgeusia Nutrition 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000013401 experimental design Methods 0.000 description 1
239000000835 fiber Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000001914 filtration Methods 0.000 description 1
210000000245 forearm Anatomy 0.000 description 1
210000001156 gastric mucosa Anatomy 0.000 description 1
230000007160 gastrointestinal dysfunction Effects 0.000 description 1
238000003304 gavage Methods 0.000 description 1
238000002695 general anesthesia Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
230000004110 gluconeogenesis Effects 0.000 description 1
210000005205 gut mucosa Anatomy 0.000 description 1
210000004524 haematopoietic cell Anatomy 0.000 description 1
231100000226 haematotoxicity Toxicity 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
238000011540 hip replacement Methods 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
235000014304 histidine Nutrition 0.000 description 1
230000003284 homeostatic effect Effects 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
235000003642 hunger Nutrition 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000001096 hypoplastic effect Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003871 intestinal function Effects 0.000 description 1
208000003243 intestinal obstruction Diseases 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
235000019626 lipase activity Nutrition 0.000 description 1
239000002960 lipid emulsion Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
230000003908 liver function Effects 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
235000020281 long black Nutrition 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
230000001071 malnutrition Effects 0.000 description 1
235000000824 malnutrition Nutrition 0.000 description 1
241001515942 marmosets Species 0.000 description 1
239000002609 medium Substances 0.000 description 1
229940057917 medium chain triglycerides Drugs 0.000 description 1
210000003975 mesenteric artery Anatomy 0.000 description 1
210000004249 mesenteric artery inferior Anatomy 0.000 description 1
210000000713 mesentery Anatomy 0.000 description 1
230000006371 metabolic abnormality Effects 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000037323 metabolic rate Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
235000021243 milk fat Nutrition 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
230000037023 motor activity Effects 0.000 description 1
230000021332 multicellular organism growth Effects 0.000 description 1
230000008693 nausea Effects 0.000 description 1
238000013188 needle biopsy Methods 0.000 description 1
231100000417 nephrotoxicity Toxicity 0.000 description 1
230000002182 neurohumoral effect Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
230000000474 nursing effect Effects 0.000 description 1
235000006286 nutrient intake Nutrition 0.000 description 1
208000015380 nutritional deficiency disease Diseases 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
239000003538 oral antidiabetic agent Substances 0.000 description 1
229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
239000012285 osmium tetroxide Substances 0.000 description 1
229910000489 osmium tetroxide Inorganic materials 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
230000004203 pancreatic function Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
WZJVQUUBEVDURL-UHFFFAOYSA-N pentanedial;phosphoric acid Chemical compound OP(O)(O)=O.O=CCCCC=O WZJVQUUBEVDURL-UHFFFAOYSA-N 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
231100000683 possible toxicity Toxicity 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
229940103147 propet Drugs 0.000 description 1
239000003531 protein hydrolysate Substances 0.000 description 1
235000021075 protein intake Nutrition 0.000 description 1
ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000003938 response to stress Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
210000005241 right ventricle Anatomy 0.000 description 1
239000011833 salt mixture Substances 0.000 description 1
238000005070 sampling Methods 0.000 description 1
230000000580 secretagogue effect Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229920000260 silastic Polymers 0.000 description 1
231100000245 skin permeability Toxicity 0.000 description 1
238000000527 sonication Methods 0.000 description 1
229940001941 soy protein Drugs 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
230000003393 splenic effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000037351 starvation Effects 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
239000012085 test solution Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
235000021076 total caloric intake Nutrition 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
239000011573 trace mineral Substances 0.000 description 1
235000013619 trace mineral Nutrition 0.000 description 1
238000005891 transamination reaction Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000005945 translocation Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
230000004102 tricarboxylic acid cycle Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000007306 turnover Effects 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Immunology (AREA)
Endocrinology (AREA)
Nutrition Science (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Packaging Of Machine Parts And Wound Products (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Looms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Compounds Of Unknown Constitution (AREA)
Seasonings (AREA)

IL9454990A 1989-06-02 1990-05-29 A pharmaceutical preparation containing glutamine IL94549A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US36083989A	1989-06-02	1989-06-02

Publications (2)

Publication Number	Publication Date
IL94549A0 IL94549A0 (en)	1991-03-10
IL94549A true IL94549A (en)	1996-08-04

Family

ID=23419606

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9454990A IL94549A (en)	1989-06-02	1990-05-29	A pharmaceutical preparation containing glutamine

Country Status (16)

Country	Link
EP (1)	EP0401056B2 (de)
JP (4)	JP3068644B2 (de)
KR (1)	KR0178799B1 (de)
AT (1)	ATE160089T1 (de)
AU (1)	AU641403B2 (de)
DE (1)	DE69031694T3 (de)
DK (1)	DK0401056T4 (de)
ES (1)	ES2111529T5 (de)
FI (1)	FI915677A0 (de)
GR (1)	GR3025678T3 (de)
HU (1)	HU220214B (de)
IL (1)	IL94549A (de)
NO (1)	NO914730D0 (de)
PT (1)	PT94223B (de)
WO (1)	WO1990014823A1 (de)
ZA (1)	ZA904151B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9002732D0 (sv) *	1990-08-24	1990-08-24	Kabivitrum Ab	Product containing growth factor
JPH0569836U (ja) *	1992-02-25	1993-09-21	松下電工株式会社	ピアノハンドル式スイッチ
US5438075A (en)	1993-03-30	1995-08-01	Skubitz; Keith M.	Oral glutamine to reduce stomatitis
US6001878A (en) *	1994-01-11	1999-12-14	Van Leeuwen; Paulus Aloisius Marie	Method of treating disorders of the animal or human body by administering amino acids
DE10057290B4 (de) *	2000-11-17	2004-01-08	Fresenius Kabi Deutschland Gmbh	Enteral zu verabreichendes Supplement zur parenteralen Ernährung oder partiellen enteralen/oralen Ernährung bei kritisch Kranken, chronisch Kranken und Mangelernährten
GB0114419D0 (en) *	2001-06-13	2001-08-08	Mars Uk Ltd	Health food
JP5473190B2 (ja) *	2003-10-16	2014-04-16	ネステクソシエテアノニム	化学療法又は放射線療法の副作用に対する栄養組成物
KR101487852B1 (ko) *	2006-12-15	2015-01-29	티마 파운데이션	신규조성물 및 그 용도
US8633192B2 (en)	2006-12-15	2014-01-21	Tima Foundation	Compositions and uses thereof
EP2612560A1 (de)	2012-01-09	2013-07-10	N.V. Nutricia	Glutaminangereicherte Ernährungszusammensetzung für frühgeborene Kinder

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1285491C (en) *	1985-09-12	1991-07-02	Robert J. Smith	Method of treating catabolic dysfunction

1990
- 1990-05-29 IL IL9454990A patent/IL94549A/en active IP Right Grant
- 1990-05-30 ZA ZA904151A patent/ZA904151B/xx unknown
- 1990-05-31 PT PT94223A patent/PT94223B/pt not_active IP Right Cessation
- 1990-06-04 ES ES90306062T patent/ES2111529T5/es not_active Expired - Lifetime
- 1990-06-04 HU HU719/90A patent/HU220214B/hu unknown
- 1990-06-04 JP JP2508838A patent/JP3068644B2/ja not_active Ceased
- 1990-06-04 AT AT90306062T patent/ATE160089T1/de not_active IP Right Cessation
- 1990-06-04 DK DK90306062T patent/DK0401056T4/da active
- 1990-06-04 KR KR1019910701759A patent/KR0178799B1/ko not_active Ceased
- 1990-06-04 AU AU58271/90A patent/AU641403B2/en not_active Expired
- 1990-06-04 WO PCT/US1990/003095 patent/WO1990014823A1/en not_active Ceased
- 1990-06-04 EP EP90306062A patent/EP0401056B2/de not_active Expired - Lifetime
- 1990-06-04 DE DE69031694T patent/DE69031694T3/de not_active Expired - Lifetime
1991
- 1991-12-02 NO NO914730A patent/NO914730D0/no unknown
- 1991-12-02 FI FI915677A patent/FI915677A0/fi unknown
1997
- 1997-12-16 GR GR970403327T patent/GR3025678T3/el unknown
2000
- 2000-02-16 JP JP2000038890A patent/JP3113876B2/ja not_active Expired - Lifetime
- 2000-02-16 JP JP2000038896A patent/JP3113878B2/ja not_active Expired - Lifetime
- 2000-02-16 JP JP2000038891A patent/JP3113877B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP2000186035A (ja)	2000-07-04
HU220214B (hu)	2001-11-28
JPH05500655A (ja)	1993-02-12
ES2111529T5 (es)	2007-11-16
JP3113878B2 (ja)	2000-12-04
JP3113876B2 (ja)	2000-12-04
KR920700629A (ko)	1992-08-10
EP0401056B1 (de)	1997-11-12
JP3068644B2 (ja)	2000-07-24
DK0401056T4 (da)	2007-07-16
ES2111529T3 (es)	1998-03-16
JP3113877B2 (ja)	2000-12-04
NO914730D0 (no)	1991-12-02
EP0401056A2 (de)	1990-12-05
DK0401056T3 (da)	1998-07-27
EP0401056A3 (de)	1991-09-25
JP2000198733A (ja)	2000-07-18
AU641403B2 (en)	1993-09-23
GR3025678T3 (en)	1998-03-31
IL94549A0 (en)	1991-03-10
AU5827190A (en)	1991-01-07
HUT61193A (en)	1992-12-28
KR0178799B1 (ko)	1999-03-20
DE69031694T2 (de)	1998-03-12
PT94223A (pt)	1991-02-08
PT94223B (pt)	1997-04-30
WO1990014823A1 (en)	1990-12-13
JP2000186034A (ja)	2000-07-04
DE69031694D1 (de)	1997-12-18
ATE160089T1 (de)	1997-11-15
FI915677A0 (fi)	1991-12-02
EP0401056B2 (de)	2007-06-13
ZA904151B (en)	1991-03-27
DE69031694T3 (de)	2007-10-18

Legal Events

Date	Code	Title
1997-01-10	FF	Patent granted
1997-06-10	KB	Patent renewed
2000-08-31	KB	Patent renewed
2004-06-20	KB	Patent renewed
2008-08-10	KB	Patent renewed

Publication	Publication Date	Title
US5039704A (en)	1991-08-13	Method of treating catabolic dysfunction
US5607975A (en)	1997-03-04	Method of treating catabolic, gut-associated pathological processes and impaired host defenses
US5397803A (en)	1995-03-14	Use of glutamine to reduce rate of pathogenic microorganism infection
US4857555A (en)	1989-08-15	Method of treating catabolic dysfunction
Fuentes-Orozco et al.	2004	L-alanyl-L-glutamine-supplemented parenteral nutrition improves infectious morbidity in secondary peritonitis
Williams et al.	1944	Thiouracil. Its absorption, distribution, and excretion
CA1285491C (en)	1991-07-02	Method of treating catabolic dysfunction
US4703062A (en)	1987-10-27	Parenteral nutrition with medium and long chain triglycerides
Diaz et al.	2019	Long-term safety and efficacy of glycerol phenylbutyrate for the management of urea cycle disorder patients
AU641403B2 (en)	1993-09-23	Method of treating catabolic, gut-associated pathological processes and impaired host defenses
Nightingale	1995	The short-bowel syndrome
Fleming et al.	1976	Subject review: total parenteral nutrition
US5763485A (en)	1998-06-09	Method of treating catabolic, gut-associated pathological processes and impaired host defenses
CA2057055C (en)	2002-01-15	Method of treating catabolic, gut-associated pathological processes and impaired host defenses
CN1822827B (zh)	2012-03-28	α-酮戊二酸用于治疗营养不良或高血浆葡萄糖症状的用途
PARKINSON et al.	1973	SHORT SMALL‐BOWEL SYNDROME
Harris	2007	Neonatal short bowel syndrome
MacDonald et al.	1976	The Long‐Term Management of Cystinuria
NO871935L (no)	1987-07-09	Fremgangsmaate for behandling av katabolisk dysfunksjon.
Goulet et al.	2004	Parenteral nutrition in infants and children
Evans	1990	Tumour necrosis factor as a mediator of endotoxaemia
Wilmore	1999	Metabolism and nutrition in the critically ill: steps for the future
HK1093016B (en)	2012-10-19	Use of alpha-ketoglutaric acid for the treatment of malnutrition or high plasma glucose condition
HK1093016A1 (en)	2007-02-23	Use of alpha-ketoglutaric acid for the treatment of malnutrition or high plasma glucose condition
HK1124553A (en)	2009-07-17	Use of alpha-ketoglutaric acid for the treatment of malnutrition or high plasma glucose condition